Terms: = Breast cancer AND CDKN1B, CDKN4, 1027, ENSG00000111276, MEN4, P27KIP1, P46527, MEN1B, KIP1 AND Prognosis
79 results:
1. Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients.
El Sharouni MA; Scolyer RA; van Gils CH; Ch'ng S; Nieweg OE; Pennington TE; Saw RP; Shannon K; Spillane A; Stretch J; Witkamp AJ; Sigurdsson V; Thompson JF; van Diest PJ; Lo SN
Eur J Cancer; 2022 May; 167():133-141. PubMed ID: 35216870
[TBL] [Abstract] [Full Text] [Related]
2. Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy.
Oner G; Önder S; Karatay H; Ak N; Tükenmez M; Müslümanoğlu M; İğci A; Dincçağ A; Özmen V; Aydiner A; Yavuz E; Cabioğlu N
World J Surg Oncol; 2021 Sep; 19(1):264. PubMed ID: 34474671
[TBL] [Abstract] [Full Text] [Related]
3. LncRNA ZFAS1 inhibits triple-negative breast cancer by targeting STAT3.
Sharma U; Barwal TS; Khandelwal A; Malhotra A; Rana MK; Singh Rana AP; Imyanitov EN; Vasquez KM; Jain A
Biochimie; 2021 Mar; 182():99-107. PubMed ID: 33429003
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive Genomic Profile of Heterogeneous Long Follow-Up Triple-Negative breast cancer and Its Clinical Characteristics Shows DNA Repair Deficiency Has Better Prognostic.
Rojas-Jiménez E; Mejía-Gómez JC; Díaz-Velásquez C; Quezada-Urban R; Martínez Gregorio H; Vallejo-Lecuona F; de la Cruz-Montoya A; Porras Reyes FI; Pérez-Sánchez VM; Maldonado-Martínez HA; Robles-Estrada M; Bargalló-Rocha E; Cabrera-Galeana P; Ramos-Ramírez M; Chirino YI; Alonso Herrera L; Terrazas LI; Oliver J; Frecha C; Perdomo S; Vaca-Paniagua F
Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33227964
[TBL] [Abstract] [Full Text] [Related]
5. Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27
Chen Y; Du M; Yusuying S; Liu W; Tan Y; Xie P
Exp Cell Res; 2020 Jul; 392(2):112038. PubMed ID: 32360865
[TBL] [Abstract] [Full Text] [Related]
6. CDK7 Inhibition is Effective in all the Subtypes of breast cancer: Determinants of Response and Synergy with EGFR Inhibition.
McDermott MSJ; Sharko AC; Munie J; Kassler S; Melendez T; Lim CU; Broude EV
Cells; 2020 Mar; 9(3):. PubMed ID: 32155786
[TBL] [Abstract] [Full Text] [Related]
7. KLF5 regulated lncRNA RP1 promotes the growth and metastasis of breast cancer via repressing p27kip1 translation.
Jia X; Shi L; Wang X; Luo L; Ling L; Yin J; Song Y; Zhang Z; Qiu N; Liu H; Deng M; He Z; Li H; Zheng G
Cell Death Dis; 2019 May; 10(5):373. PubMed ID: 31073122
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic significance of LAPTM4B and p27kip1 expression in triple-negative breast cancer.
Li X; Song C; Wang K; Li N; Sun S; Li N; Zhao Z; Li M
Cancer Biomark; 2019; 25(1):19-27. PubMed ID: 31033460
[TBL] [Abstract] [Full Text] [Related]
9. A model for anticancer surveillance was pharmacologically developed to evaluate vitality principle in breast cancer rats.
Liu J; Zhao X; Ge S; Li S; Chen C; Li X; Lin Y; Cai D; Peng L; Mu Y; Zhang R; Feng X; Wang Y; Deng B; Jia L; Cheng Z; Zhang M; TaeHoo Y
J Tradit Chin Med; 2018 Dec; 38(6):823-833. PubMed ID: 32186129
[TBL] [Abstract] [Full Text] [Related]
10. Loss of p27
Kim GJ; Kim DH; Min KW; Kim YH; Oh YH
Pathol Res Pract; 2018 Apr; 214(4):565-571. PubMed ID: 29482985
[TBL] [Abstract] [Full Text] [Related]
11. Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2
D'Alesio C; Bellese G; Gagliani MC; Aiello C; Grasselli E; Marcocci G; Bisio A; Tavella S; Daniele T; Cortese K; Castagnola P
J Exp Clin Cancer Res; 2017 Nov; 36(1):154. PubMed ID: 29100552
[TBL] [Abstract] [Full Text] [Related]
12. Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers.
Song W; Hwang Y; Youngblood VM; Cook RS; Balko JM; Chen J; Brantley-Sieders DM
Oncogene; 2017 Oct; 36(40):5620-5630. PubMed ID: 28581527
[TBL] [Abstract] [Full Text] [Related]
13. [Expression and clinical significance of Ser10 phosphorylated p27(kip1) protein in human breast carcinoma].
Guo ZQ; Lü QS; Wang Z; Lu LH; Lu N; Wen XW; Wu WX; Yao M
Zhonghua Yi Xue Za Zhi; 2017 May; 97(18):1396-1399. PubMed ID: 28535625
[No Abstract] [Full Text] [Related]
14. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27
Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH
Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665
[TBL] [Abstract] [Full Text] [Related]
15. Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome-wide shRNA screen.
Kurahara H; Bohl C; Natsugoe S; Nishizono Y; Harihar S; Sharma R; Iwakuma T; Welch DR
Int J Cancer; 2016 Aug; 139(3):628-38. PubMed ID: 27012470
[TBL] [Abstract] [Full Text] [Related]
16. ER, PgR, Ki67, p27(kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
Kurozumi S; Inoue K; Takei H; Matsumoto H; Kurosumi M; Horiguchi J; Takeyoshi I; Oyama T
BMC Cancer; 2015 Sep; 15():622. PubMed ID: 26345461
[TBL] [Abstract] [Full Text] [Related]
17. Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Wang Y; Wu Y; Miao X; Zhu X; Miao X; He Y; Zhong F; Ding L; Liu J; Tang J; Huang Y; Xu X; He S
Int J Biol Macromol; 2015 Nov; 81():809-17. PubMed ID: 26341817
[TBL] [Abstract] [Full Text] [Related]
18. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.
Elster N; Collins DM; Toomey S; Crown J; Eustace AJ; Hennessy BT
Breast Cancer Res Treat; 2015 Jan; 149(1):5-15. PubMed ID: 25542271
[TBL] [Abstract] [Full Text] [Related]
19. Decreased expression and prognostic role of cytoplasmic BRSK1 in human breast carcinoma: correlation with Jab1 stability and PI3K/Akt pathway.
Wang H; Liu XB; Chen JH; Wang QQ; Chen JP; Xu JF; Sheng CY; Ni QC
Exp Mol Pathol; 2014 Oct; 97(2):191-201. PubMed ID: 25036402
[TBL] [Abstract] [Full Text] [Related]
20. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
[TBL] [Abstract] [Full Text] [Related]
[Next]
